For instance, some authors (Patel and Klein 2011; Bankston et al. 2013; Scalabrino et al. 2015; Nicoletti et al. 2019; Villoslada and Steinman 2020) have argued that EGF could theoretically be used (alone or together other myelinotrophic molecules) as a physiological enhancer of CNS remyelination in patients with MS. Here, EGF is linked to myeloid sarcoma.